Se nyheter från:
Feb 11, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today presented positive results from a preclinical study in the research project QPG-1029 (pegylated liraglutide), for the treatment of type 2 diabetes and overweight. The study evaluated the pharmacokinetic properties of QPG-1029 after intravenous and subcutaneous administration in rats.

Jan 28, 2020

In accordance with a decision at the Annual General Meeting on May 29, 2019 in QuiaPEG Pharmaceuticals Holding AB, the three members of the Nomination Committee for the 2019 Annual General Meeting shall be appointed by the Company's two largest shareholders, according to voting rights, as of September 30, 2019, each entitled to nominate one member of the Nomination Committee. As the company's holders of the most shares declined to appoint a member to the nomination committee, Marcus Bosson, as the third largest shareholder, may therefore appoint a member. In addition, the Nomination Committee shall consist of one member appointed by the Board of Directors.

Jan 28, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG") has previously announced that the company's annual report for the period January-December 2019 will be published on March 6th, 2020. The Board of Directors of QuiaPEG has now decided to bring forward the date for publication of the interim report to February 28th, 2020.

Oct 23, 2019

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or already approved drugs, so-called. biobetters. This is done on the basis of the company's own patent-protected technology platform, Uni-Qleaver®, which makes it possible to control a drug's release through a degradable chemical linker.

QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message